US Patent

US8821927 — Pharmaceutical composition

Composition of Matter · Assigned to SmithKline Beecham Cork Ltd · Expires 2029-09-18 · 3y remaining

Vulnerability score 15/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines for treating disorders with aberrant erbB family PTK activity.

USPTO Abstract

Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.

Drugs covered by this patent

lapatinib-ditosylate (LAPATINIB DITOSYLATE)

Patent Metadata

Patent number: US8821927
Jurisdiction: US
Classification: Composition of Matter
Expires: 2029-09-18
Drug substance claim: Yes
Drug product claim: Yes
Assignee: SmithKline Beecham Cork Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.